Bootleg Retatrutide Linked to Two Deaths Reported to FDA

Bootleg retatrutide just landed in the middle of a very real safety scare. The FDA received reports in recent months that two people died after taking products sold as retatrutide, an experimental weight-loss drug that no regulator has approved, according to a CBS News investigation that obtained the documents through a Freedom of Information Act request.

Here is the catch that matters most: nobody has proven the drug caused either death. The reports are unverified, and the FDA would not say whether it had checked any of the details. Still, if you have scrolled past peptide ads on social media lately, this story is about the exact stuff being pushed to you.

What the two death reports actually say

The first report was filed in July by a health care professional. It describes a forty-one-year-old woman with obesity who went into cardiac arrest. She arrived at a hospital with a dangerously fast heartbeat and died after repeated attempts to revive her failed. The report lists retatrutide as a suspect product and says she got it from an unreliable source. It also notes she had been drinking kava, a plant-based relaxant, which muddies the picture.

The second report arrived in September. It describes a forty-nine-year-old patient who died after severe dehydration, malnutrition and cardiac arrest. According to the report, a licensed nurse sold her vials, sent her the link and suggested doses. A vial pictured in the paperwork carried the name of an online peptide seller. An attorney for that company told CBS there was not enough information to tie the vial to its products and that the image does not match its current packaging.

Adverse event reports are early warning signals, not verdicts. Anyone can file one, details are often thin, and the FDA blacked out identifying information. Neither death was linked to a clinical trial, according to the documents and Eli Lilly.

The numbers behind the scare

The bigger signal may be the poison center data. America's Poison Centers logged eight hundred sixty-two exposures to retatrutide in the three months ending in September, according to Medical Daily, which was citing CBS News. That is up from four hundred sixty in the three months before, and two hundred forty-nine in the first three months of this year. Some of that climb is normal for a newly tracked drug, but the jump is steep.

A June investigation by the watchdog group Public Citizen, as described by Medical Daily, found the FDA had sent fourteen warning letters to retatrutide sellers since the start of 2024, yet eight of those companies were still selling it as of May. The group also pointed to hundreds of influencers working as sales affiliates.

Why the real drug and the online vials are not the same thing

Retatrutide is a once-weekly shot from Eli Lilly that hits three hormone pathways at once: GIP, GLP-1 and glucagon. In its phase three obesity trial, people on the top dose lost an average of twenty-eight point three percent of their body weight over eighty weeks, according to Lilly's trial announcement. Those numbers are why the drug has become a social media obsession.

But that result came from screened volunteers who started on low doses and were watched closely by clinicians. It was also company-funded research, and regulators have not reviewed the drug yet. Lilly says it plans to file with the FDA in early 2027.

Vials bought online are a different animal. Lilly told CBS that suspect products it has tested contained too much, too little or the wrong active ingredient, along with contaminants. The company said the reported deaths "make clear the two individuals were taking black-market retatrutide." Lilly is also suing companies over alleged sales, and those claims have not been decided in court.

Why the medical world is alarmed

Pieter Cohen, an associate professor at Harvard Medical School, told CBS: "It is concerning because of the breakdown of our drug-approval process in the United States of America." He argued the FDA should get hold of the actual product the patients injected and have it analyzed.

The side effects in Lilly's trial were mostly digestive, including nausea, diarrhea, constipation and vomiting. Those sound minor until you remember that severe vomiting or diarrhea can drain the body of fluids fast. Add a vial of unknown strength, no doctor watching your heart rate, and maybe a shared needle, and the risk stacks up.

What to do if you or a friend already tried it

If you have used a gray-market product, tell a clinician and keep the vial and packaging so it can be identified. Questions about a reaction can go to Poison Help at the national hotline, which connects callers to poison centers. Chest pain, fainting, a racing heartbeat, nonstop vomiting, severe belly pain or signs of dehydration mean emergency care right away.

Do not stop or change prescribed medication without medical advice. If cost is what pushed anyone toward the black market, a clinician can walk through approved weight-loss options, insurance appeals and manufacturer savings programs. Suspected reactions to bootleg retatrutide can be reported to the FDA through its MedWatch program.

The next poison center tally and any FDA review of these cases will show whether the trend is slowing. Until then, the tested drug stays promising and unproven for public use, while bootleg retatrutide stays a gamble. For more explainers like this one, check our health coverage.